60
Participants
Start Date
April 29, 2019
Primary Completion Date
December 31, 2024
Study Completion Date
June 30, 2025
intravenous lidocaine (IVL)
lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
Placebo
Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
RECRUITING
Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal, Montreal
Foundation of Anesthesia and Resuscitation of Quebec
UNKNOWN
Ciusss de L'Est de l'Île de Montréal
OTHER